<?xml version="1.0" encoding="UTF-8"?>
<p>The socioeconomic losses associated with viral infections of the respiratory tract are enormous at present. In Russia, acute respiratory infections (ARIs), including influenza, occupy a leading position for infectious diseases [
 <xref rid="B1-marinedrugs-17-00373" ref-type="bibr">1</xref>]. According to the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 27.3â€“41.2 million cases of these diseases are registered in Russia each year. The total economic damage from ARIs in Russia ranges from 40 to 100 billion rubles annually [
 <xref rid="B2-marinedrugs-17-00373" ref-type="bibr">2</xref>]. In the United States, more than 400,000 people per year are hospitalized with respiratory viral infections [
 <xref rid="B3-marinedrugs-17-00373" ref-type="bibr">3</xref>].
</p>
